Pfizer’s COVID-19 Franchise Dominates Best-Seller List
Paxlovid Rose As Cominarty Slowed And Humira Came In Third
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.
You may also be interested in...
All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch
The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.
Moderna Highlights Near-Term Non-COVID Readouts As Pandemic Vaccine Sales Drop
The company attributed lower-than-expected vaccine sales to supply issues, but it expects some significant read-outs over the next few months in respiratory infections and oncology.
Pfizer Plans For COVID Transition And RSV Vaccine Launch
The COVID-19 vaccine and treatment market is expected to evolve into more a flu-like volume and market in 2023, but will remain a "multi-billion dollar" franchise, Bourla said.